Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic characterization of a large-scale chikungunya outbreak in China.

The Journal of infection·2026
Same author

Overexpression of the tomato SlLEA_2-26 gene enhances the tolerance todrought and salt stresses in Arabidopsis thaliana.

Journal of plant research·2026
Same author

Automated Monkeypox Identification from Electronic Medical Records Using Large Language Models - Shenzhen City, Guangdong Province, China, 2023-2025.

China CDC weekly·2026
Same author

Epidemiological Trends of COVID-19 Infection and Symptom Incidence in China Following the Adjustment of Zero-COVID Policy: A Prospective, Community-Based Cohort Study.

Transboundary and emerging diseases·2026
Same author

Independent Degeneration of Photoreceptors and Retinal Pigment Epithelium: Multimodal Imaging Evidence From Choroideremia Carriers.

Investigative ophthalmology & visual science·2026
Same author

Oral pH-responsive sodium alginate microspheres co-delivering Musca domestica cecropin and eugenol for anti-inflammatory therapy in sepsis.

International journal of biological macromolecules·2026

Related Experiment Video

Updated: Jun 18, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

[Development of glaucoma drainage device].

Xuan Zou1, Xuan-Chu Duan

  • 1Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011, China.

[Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology
|December 5, 2009
PubMed
Summary
This summary is machine-generated.

Glaucoma drainage devices (GDDs) offer moderate success for refractory glaucoma but often fail due to bleb fibrosis. Research explores antifibrotic agents and new technologies to improve long-term GDD efficacy and reduce complications.

Related Experiment Videos

Last Updated: Jun 18, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Area of Science:

  • Ophthalmology
  • Biomaterials Science

Context:

  • Glaucoma drainage devices (GDDs) are used for refractory glaucoma.
  • Bleb fibrosis is a primary cause of long-term GDD failure.
  • Histopathological studies investigate fibrosis mechanisms and clinical effects.

Purpose:

  • To review the causes of GDD failure, focusing on bleb fibrosis.
  • To discuss the efficacy and challenges of antifibrotic agents.
  • To explore emerging technologies for improving GDD outcomes.

Summary:

  • GDDs moderately reduce intraocular pressure (IOP) in refractory glaucoma but have serious complications.
  • Bleb fibrosis significantly impacts long-term GDD success.
  • Novel materials, nanotechnology, and anterior segment OCT show promise for GDD advancements.

Impact:

  • Highlights the need for improved strategies to combat GDD fibrosis.
  • Suggests potential for new treatments and surgical techniques.
  • Emphasizes the role of advanced imaging and materials in glaucoma surgery.